Rodrigo Cavallazzi, MD
Pulmonary Disease · Louisville, KYNPI 1851500961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.7%), consulting fees and charitable contributions — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Eko Health, Inc. at 38.3% of the total. Reporting peaked in 2024 at $889 and has fallen 63.6% since, to $324 in 2025. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 17 payments — averaging $157.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eko Health, Inc.$1K
- Pfizer$740
- Nabriva Therapeutics, PLC$256
- Electromed, Inc.$238
- Pulmonx Corporation$148
- Avadel CNS Pharmaceuticals, LLC$120
- plus $153 from 5 others
Across 13 payments — averaging $3099.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shionogi Inc$19K
- Pfizer$15K
- AstraZeneca$4K
- Melinta Therapeutics, LLC$2K
What the payments were for
- Consulting fees$74028%
- Food & beverage$90334%
- Education$120%
- Charitable contribution$59822%
- Other$42916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eko Health, Inc. | 2 | $1,027 |
| Pfizer | 1 | $740 |
| Nabriva Therapeutics, PLC | 1 | $256 |
| Electromed, Inc. | 3 | $238 |
| Pulmonx Corporation | 1 | $148 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $120 |
| Johnson & Johnson | 2 | $55 |
| Boehringer Ingelheim | 3 | $50 |
| Verona Pharma, Inc. | 1 | $23 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$740
- Xenleta$256
- SMARTVEST$235
- Pulmonx Endobronchial Valve EBV$148
- LUMRYZ$120
How this compares
$2,682 in reported general payments places this provider in the 40th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $133,203 |
| Dupixent PenDupilumab | 23 | $82,811 |
| Spiriva RespimatTiotropium Bromide | 55 | $42,796 |
| NucalaMepolizumab | 12 | $41,835 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $40,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $35,589 |
| Spiriva HandihalerTiotropium Bromide | 28 | $29,666 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $22,043 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $19,860 |
| EliquisApixaban | 16 | $15,003 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $13,341 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $11,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 350 | $9,234 |
| DuleraMometasone/Formoterol | 24 | $7,964 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 38 | $7,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $13 | $251,113256 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $12 | $55,44990 claims |
| Boehringer IngelheimSpiriva Respimat | $50 | $42,79655 claims |
| PfizerEliquis | $740 | $15,00316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.